Biochemical aspects of drug combinations.
D000477:Alkylating Agents / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002166:Camptothecin / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003676:Deferoxamine / Q000627:therapeutic use; D003959:Diamines / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy / Q000401:mortality; D046911:Macromolecular Substances; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011685:Purine Nucleotides / Q000096:biosynthesis; D012264:Ribonucleotide Reductases / Q000032:analysis; D013866:Thioguanine / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D014230:Triazoles / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D003959:Diamines; D046911:Macromolecular Substances; D009607:Nitrosourea Compounds; D011685:Purine Nucleotides; D014230:Triazoles; D003561:Cytarabine; D001761:Bleomycin; D004317:Doxorubicin; D012264:Ribonucleotide Reductases; D013866:Thioguanine; D003676:Deferoxamine; D002166:Camptothecin